-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Elvitegravir-d8
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/elvitegravir-d8.gif)
| Category | HIV Integrase |
| Description | Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB , HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively. |
Product Information
| Synonyms | Elvitegravir-d8|HY-14740S|CS-0377379 |
| Molecular Weight | 455.93 |
| Molecular Formula | C23H23ClFNO5 |
| Canonical SMILES | CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O |
| Boiling Point | 658.8±55.0 °C at 760 mmHg |
| Flash Point | 352.2±31.5 °C |
| Purity | ≥98% (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 702 |
| Exact Mass | 455.1750927 |
| Index Of Refraction | 1.619 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | IC50: 0.7 nM (HIV-1IIIB), 2.8 nM (HIV-2EHO), 1.4 nM(HIV-2ROD) |
| Vapor Pressure | 0.0±2.1 mmHg at 25°C |
| XLogP3-AA | 5.3 |
